Sanofi Consumer Healthcare India Q1 PAT up 12.9%

The Q1 2025 also witnessed a successful launch of Allegra D

Vimta Labs posts Q4 FY25 PAT at Rs. 18.31 Cr

Vimta Labs has reported total income of Rs. 96.08 crores during the period ended March 31, 2025

Sigachi Industries signs MoU with Respilon Group

This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies.

USFDA inspects Marksans’s subsidiary Time-Cap Laboratories' manufacturing facility

The Subsidiary has received one inspectional observation in Form 483

CHMP recommends EU label update for Roche’s Phesgo to allow administration outside of clinical settings

Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings

Aster DM Healthcare completes acquisition of 5% stake in Quality Care India

The transaction structured as share swap, is valued at ~Rs. 849 crore, with no cash outflow

Gland Pharma receives USFDA approval for Latanoprostene Bunod Ophthalmic Solution

This Product is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension

Indegene posts Q4 FY25 consolidated PAT at Rs. 117.6 Cr

The company has posted net profit of Rs. 406.7 crores for the Financial Year ended March 31, 2025

Morepen to launch new fatty lever drug ‘Resmetirom’

Merck to acquire US Biopharma firm SpringWorks Therapeutics for enterprise value of $3.4 billion

Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide